Printer Friendly Printed from http://www.researchandmarkets.com/reports/466590 Emerging Opportunities in Inhalation & Nasal Spray Generic Drugs Description: Exciting opportunities in this high growth area can be expected over the next 10 years. At least nine significant products will lose patent protection in key markets and this number could increase depending on the outcome of patent challenges. The inhalation and intranasal drugs discussed in this new report had combined sales exceeding US$18 billion in 2006. These drugs are used in the treatment of asthma, COPD, allergic rhinitis, influenza, migraine and osteoporosis, and in general anaesthesia. More importantly, from a generic industry perspective is that at least 9 significant products will lose patent protection in key markets over the next 10 years, and this number could increase depending on the outcome of patent challenges. The generics market is undergoing radical restructuring, with much rationalisation of the corporate landscape. In such a competitive cauldron companies are now seeking not just new opportunities but opportunities which combine good profit levels and a degree of product novelty - both of which are available in the inhalation and nasal spray market. IDENTIFY THE OPPORTUNITIES AND THE COMPANIES INVOLVED This new report provides industry planners, commercial developers and the investment community with a thorough review of the potential for generic inhalation and nasal spray drugs over the next 5 years. Packed with primary source information and original market forecasts, it takes a balanced view of the players and products that will shape this high value market sector. THE REPORT PROVIDES... - Full 5-year product/market forecasts by value to 2011 - Generic market context - Reviews of 18 leading players - Analysis of significant litigation - Patent expiry opportunities to 2016 JUST SOME OF THE QUESTIONS ANSWERED BY THE REPORT: - What are the most promising future product opportunities and when do they lose patent protection? - What drug delivery challenges must companies overcome if they are to really benefit in the marketplace? - What will be the effect on the value of GSK’s blockbusting Advair in 2011 assuming generic competition starts in 2008? - Which therapy areas offer the best potential for ANDA development? Contents: Foreword Executive Summary Generic Market Overview Inhalation and Nasal Spray Drug Delivery Asthma and COPD Allergic rhinitis Influenza Diabetes Pain, Migraine and other CNS disorders Osteoporosis Anaesthesia Pulmonary arterial hypertension Nocturia Potential inhalation drugs for anthrax, cystic fibrosis and erectile dysfunction Critical Path Opportunities for Generic Drugs in the US Asthma & COPD Flixotide/Flovent (fluticasone propionate Market Outlook Serevent (salmeterol xinafoate) Market Outlook Seretide/Advair (salmeterol xinafoate+fluticasone propionate) Patents Patent Challenge Safety Issues Market Outlook Pulmicort (budesonide) Patent Challenge Market Outlook Combivent (ipratropium bromide+salbutamol) Market Outlook Xopenex (levalbuterol) Patent Challenges Market Outlook Allergic rhinitis Flixonase (fluticasone propionate) Generic Competition Market Outlook INHALATION & NASAL SPRAY GENERIC DRUGS Rhinocort (budesonide) Market Outlook Nasonex (mometasone furoate) Market Outlook Nasacort (triamcinolone acetonide) Patent Challenge Market Outlook Influenza Relenza (zanamivir) Litigation Market Outlook Migraine Imigran (sumatriptan) Patents Generic Competition Market Outlook Zomig (zolmitriptan) Patents Market Outlook Osteoporosis Miacalcin (calcitonin-salmon) Further Development Patents & Generic Activity Fortical (calcitonin-salmon [rDNA origin]) Generic Activity Market Outlook Anaesthesia Ultane (sevoflurane) Generic Competition Market Outlook Suprane (desflurane) Generic Competition Company Profiles Amphastar Pharmaceuticals Products Apotex Inhalation and Nasal Spray Products Barr Pharmaceuticals Product Development INHALATION & NASAL SPRAY GENERIC DRUGS Financials Baxter Healthcare Inhalation Products Financials Acquisitions Beximco Pharmaceuticals Products Financials Cipla Products Financials Hi-Tech Pharmacal Products Financials Hovione FarmaCiencia Products Financials Merck Generics Financials Products Dey Inhalation and Nasal Spray Products Financials Morton Grove Pharmaceuticals Inhalation Products Nephron Pharmaceuticals Products Ranbaxy Laboratories Products Financials Roxane Laboratories Products Financials RxElite Products Sandoz Inhalation Products Financials INHALATION & NASAL SPRAY GENERIC DRUGS Teva Pharmaceutical Industries Products Asthma & COPD Allergic Rhinitis. Financials Watson Pharmaceuticals Products Financials SOURCES Espicom Sources Others INHALATION & NASAL SPRAY GENERIC DRUGS List of Tables Generic Pharmaceutical Expenditure in Leading Markets, 2006 Leading Generic Drug Markets, 2006-2011 (US$ Millions) Population of Leading Generic Markets, 2006-2011 (000s) Per Capita Expenditure in Leading Generic Drug Markets, 2006-2011 (US$) US Patent Expiry for Major Inhalation and Nasal Spray Drugs, 2006-2017 FDA ANDA Approvals of Inhalation and Nasal Spray Generics, 2002-2007 FDA Tentative ANDA Approvals of Inhalation and Nasal Spray Generics, 2007 US Patent Expiry for Major Asthma and COPD Inhalable Therapies; 2006 Sales (US$ Millions) US FDA Approved Generic Asthma/COPD Inhalation Products Flixotide/Flovent Sales, 2002-2006 (£ & US$ Million) Serevent Sales, 2002-2006 (£ & US$ Million) Seretide/Advair Sales, 2002-2006 (£ & US$ Million) Pulmicort Sales, 2002-2006 (US$ Million) Combivent Sales, 2002-2006 (EUR & US$ Million) Xopenex Sales, 2002-2006 (US$ Million) US Patent Expiry for Selected Nasal Spray Allergy Therapies; 2006 Sales (US$ Millions) US FDA Approved Generic Allergic Rhinitis Nasal Spray Products Flixonase/Flonase Sales, 2002-2006 (£ & US$ Million) Rhinocort Sales, 2002-2006 (US$ Million) Nasonex Sales, 2002-2006 (US$ Million) Nasacort Sales, 2002-2006 (EUR & US$ Million) Relenza Sales, 2005-2006 (£ & US$ Millions) Imigran/Imitrex Sales, 2002-2006 (£ & US$ Million) Zomig Sales, 2002-2006 (US$ Million) Miacalcic/Miacalcin Sales, 2002-2006 (US$ Million) Ultane/Sevorane Sales, 2003-2006 (US$ Million) Apotex ANDA Approvals for Inhalable and Nasal Spray Drugs, 2001-2007 Barr Pharmaceuticals Financial Results, 2002-06 (US$ million) Baxter Healthcare ANDA Approvals for Inhalable Drugs, 2002 Baxter Financial Results, 2002-2006 (US$ Million) Beximco Pharmaceuticals Financial Results, 2005 Cipla Financial Results, 2003-2006 Hi-Tech Pharmacal Fiscal Year Results, 2005-2006 (US$ millions) Merck Generics Financial Results, 2003-06 (EUR Millions) Dey ANDA Approvals, 1987-2007 Dey Sales, 2003-2006 INHALATION & NASAL SPRAY GENERIC DRUGS Morton Grove ANDA Approval for Inhalation Products, 1999-2007 Nephron Pharmaceuticals ANDA Approvals, 1997-2007 Ranbaxy Financial Results, 2003-2006 Roxane Laboratories ANDA Approvals for Inhalation and Nasal Spray Products, 2002-2007 Roxane Net Sales, 2005-2006 (EUR & US$ Million) RxElite ANDA Approvals for Inhalation Products Sandoz ANDA Approval for Inhalation Product, 2006 Sandoz Financial Results, 2004-06 (US$ millions) Teva Financial Results, 2002-2006 (US$ millions) Watson Financial Results, 2002-2006 (US$ Million) List of Figures Per Capita Spending on Generic Pharmaceuticals, 2006 (US$) Per Capita Spending on Generic Pharmaceuticals, 2011 (US$) Flixotide/Flovent Projected Sales, 2006-2011 (US$ Million) Salmeterol Xinafoate Projected Sales, 2006-2011 (US$ Million) Salmeterol+Fluticasone Combination Projected Sales, 2006-2011 (US$ Million) Pulmicort Projected Sales, 2006-2011 (US$ Million) Combivent Projected Sales, 2006-2011 (US$ Million) Levalbuterol Projected Sales, 2006-2011 (US$ Million) Fluticasone Propionate Nasal Spray Projected Sales, 2006-2011 (US$ Million) Rhinocort Projected Sales, 2006-2011 (US$ Million) Nasonex Projected Sales, 2006-2011 (US$ Million) Triamcinolone Acetonide Nasal Spray Projected Sales, 2006-2011 (US$ Million) Imigran/Imitrex Projected Sales, 2006-2011 (US$ Million) Zomig Projected Sales, 2006-2011 (US$ Million) Calcitonin-salmon Nasal Spray Projected Sales, 2006-2011 (US$ Million) Sevoflurane Projected Sales, 2006-2011 (US$ Million) Companies Mentioned -Amphastar Pharmaceuticals -Apotex -Barr Pharmaceuticals -Baxter Healthcare -Beximco Pharmaceuticals -Cipla -Hi-Tech Pharmacal -Hovione FarmaCiencia -Merck Generics -Morton Grove Pharmaceuticals -Nephron Pharmaceuticals -Ranbaxy Laboratories -Roxane Laboratories -RxElite -Sandoz -Teva Pharmaceutical Industries -Watson Pharmaceuticals Ordering: Order Online - visit http://www.researchandmarkets.com/reports/466590 Order by Fax - using the order form below Order By Post - print the order form below and send to Research and Markets, Guinness Centre, Taylors Lane, Dublin 8, Ireland. Page 1 of 2 Printed 29/08/2008 06:47:11 Fax Order Form To place an order via fax simply print this form, fill in the information below and fax the completed form to the number at the bottom of this page. If you have any questions please email help@researchandmarkets.com Order information Please verify that the product information is correct and select the format you require. Product Name: Emerging Opportunities in Inhalation & Nasal Spray Generic Drugs Web Address: http://www.researchandmarkets.com/reports/466590 Office Code: OCHGLLPKURY Report formats Please enter the quantity of the report format you require. Format Quantity Price Electronic (PDF) €1,495.00 Hard Copy €1,495.00 + EUR€ 50.00 Shipping/Handling * * Shipping/Handling is only charged once per order. Contact information Please enter all the information below in BLOCK CAPITALS. First Name:   Last Name:   Email Address: Job Title: Organisation: Address: City: Postal/Zip Code: Country: Phone Number: Fax Number: Please fax this form to: (646)607-1907 or (646)964-6609 - From USA +353-1-481-1716 or +353-1-653-1571 - From Rest of World Page 2 of 2 Printed 29/08/2008 06:47:11 Payment information Please indicate the payment method you would like to use by selecting the appropriate box.  Pay by Credit Card: American Express Diners Club Master Card Visa Cardholder Name: Expiry Date: / Card Number: CVV Security Code: Issue Date: /   (Diners Club only)  Pay by Check: Please post the check, accompanied by this form, to: Research and Markets, Guinness Centre, Taylors Lane, Dublin 8, Ireland.  Pay by Wire Transfer: Please transfer funds to: Account number: 83313083 Sort code: 98-53-30 Swift code: ULSBIE2D IBAN number: IE78ULSB98533083313083 Bank Address: Ulster Bank, 27-35 Main St, Blackrock, Co. Dublin, Ireland. If you have a Marketing Code please enter it below: Marketing Code: Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp Please fax this form to: (646)607-1907 or (646)964-6609 - From USA +353-1-481-1716 or +353-1-653-1571 - From Rest of World